One site for Breaking News, Politics, Sports, Entertainment & more!

Newz Chooze
Back

Gossamer Bio opened for trading at $19 a share, an 18.8% premium to its $16 pricing. The clinical-stage biopharmaceutical raised about $276 million through the sale of 17.25 million share. Gossamer trades under the ticker "GOSS."  Gossamer Bio spiked in its trading debut on Friday.  The clinical-stage biopharmaceutical company that focuses on "discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology" opened for trading at $19 a share — an 18.8% premium to Thursday evening's $16 pricing. The sale of 17.25 million shares raised about $276 million, according to a press release out Thursday evening. BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI were  joint book-running managers for the offering. Gossamer shares will trade on the Nasdaq, under the ticker "GOSS."  Join the conversation about this story » NOW WATCH: Earth's north magnetic pole is on the move — here's what will happen when our poles flip